Life Science

An HDAC inhibitor that increases histone H3 acetylation levels in LoVo and HT-29 colon cancer cells at concentrations as low as 4 &microM dose-dependently decreases the activation of several oncogenic signaling kinases and induces cell cycle

A selective, cell-permeable, quinolone-based inhibitor of Chk1 (IC₅₀ = 0.3 nM versus 0.

A selective, cell-permeable, quinolone-based inhibitor of Chk1 (IC₅₀ = 0.3 nM versus 0.

A selective, cell-permeable, quinolone-based inhibitor of Chk1 (IC₅₀ = 0.3 nM versus 0.

A selective, cell-permeable, quinolone-based inhibitor of Chk1 (IC₅₀ = 0.3 nM versus 0.

A reversible, cell-permeable inhibitor of GSK3&alpha and GSK3&beta (IC₅₀ = 0.65 and 0.

A reversible, cell-permeable inhibitor of GSK3&alpha and GSK3&beta (IC₅₀ = 0.65 and 0.

A reversible, cell-permeable inhibitor of GSK3&alpha and GSK3&beta (IC₅₀ = 0.65 and 0.

A reversible, cell-permeable inhibitor of GSK3&alpha and GSK3&beta (IC₅₀ = 0.65 and 0.

An aminopyrimidine derivative that inhibits GSK3&alpha and GSK3&beta (IC50s = 10 and 6.7 nM, respectively) activates glycogen synthesis in CHO-IR cells (EC50 = 0.

An aminopyrimidine derivative that inhibits GSK3&alpha and GSK3&beta (IC50s = 10 and 6.7 nM, respectively) activates glycogen synthesis in CHO-IR cells (EC50 = 0.

An aminopyrimidine derivative that inhibits GSK3&alpha and GSK3&beta (IC50s = 10 and 6.7 nM, respectively) activates glycogen synthesis in CHO-IR cells (EC50 = 0.